In conclusion, our study demonstrates that the PROTAC EZH2 degrader-1 can penetrate the blood-brain barrier and overcome the resistance to podophyllotoxin derivatives (VM26) in the refractory SCLC-LM model, suggesting a potential therapeutic strategy for treating SCLC leptomeningeal metastasis. This evidence concerns the gene EZH2 and small cell lung carcinoma.